1365P A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)

Authors :: Hiroaki Okamoto
Hideki Hayashi
Shingo Miyamoto
Toshiyuki Harada
Yosuke Tanaka
H. Lihara
Naoki Furuya
Koichi Minato
Nobuhiko Seki
T. Hirose
Masanao Nakashima
Kaoru Kubota
S. Sasada
Tsuneo Shimokawa
Katsuhiko Naoki
Takaaki Tokito
Rintaro Noro
Takayuki Kaburagi
Akihiro Bessho
Satoshi Igawa
Source :: Annals of Oncology. 31:S872-S873
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Afatinib
Low dose
Hematology
medicine.disease
Egfr mutation
Internal medicine
medicine
Non small cell
Lung cancer
business
medicine.drug

Full Text Access

Tools